Analytical Data
-
Gene name
ADORA3
- Application
-
Alternative Names
A3AR; AD026
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P28647
-
Expression Region
Lys287~Glu320
-
Molecular Weight
14kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ADORA3 (Adenosine A3 receptor) is a member of the adenosine receptor family, which plays a pivotal role in various physiological processes and pathophysiological conditions. As a G protein-coupled receptor, ADORA3 is involved in modulating immune responses, inflammation, and cardioprotection, making it a potential therapeutic target for diseases such as cancer, cardiovascular disorders, and neurodegenerative diseases. The receptor's unique signaling pathways, mediated through its interaction with adenosine, have garnered significant interest in pharmacology and drug development. Recent research has focused on the characterization of recombinant ADORA3 proteins to elucidate their functional properties and to facilitate the screening of novel ligands and drugs. By producing ADORA3 in various expression systems, researchers aim to study its structure-function relationships and interactions with signaling partners. The development of ADORA3 recombinant proteins enhances our understanding of how this receptor can be modulated in a therapeutic context, paving the way for innovative treatments targeting adenosine signaling pathways. This research is critical for uncovering the role of ADORA3 in disease mechanisms and for developing effective pharmacological agents that can specifically target this receptor to improve patient outcomes.
